Related Experiment Video

Updated: May 6, 2026

Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes
07:41

Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes

Published on: October 2, 2017

7.8K

A Minireview on BET Inhibitors: Beyond Bromodomain Targeting

Mikhail S Iudin1,2, Yuri M Khodarovich3,4, Anna M Varizhuk1,2

  • 1Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.

Biomedicines
|March 28, 2025
PubMed

Insights

Non-bromodomain inhibitors offer a novel therapeutic strategy by targeting Bromodomain and extra-terminal domain (BET) proteins, which are crucial for gene transcription and implicated in diseases like cancer and viral infections.

Area of Science:

  • Epigenetics
  • Molecular Biology
  • Drug Discovery

Background:

  • Bromodomain and extra-terminal domain (BET) proteins are key epigenetic readers involved in gene transcription.
  • Dysregulation of BET proteins is linked to cancer, metabolic disorders, and viral infections, making them therapeutic targets.
  • Current research primarily focuses on bromodomain inhibition, but this approach has limitations.

Purpose of the Study:

  • To review recent advances in the development of non-bromodomain BET inhibitors.
  • To discuss the potential applications, advantages, and future perspectives of these novel inhibitors.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of emerging research on non-bromodomain BET inhibitors.
  • Synthesis of findings on therapeutic potential and challenges.

Main Results:

  • Non-bromodomain BET inhibitors offer a promising alternative to bromodomain inhibitors.
  • These inhibitors can provide better control over host and viral gene expression.
  • Targeting non-bromodomain regions may mitigate side effects associated with broad-spectrum inhibition.

Conclusions:

  • Non-bromodomain BET inhibitors represent a significant advancement in targeting BET proteins for therapeutic intervention.
  • Further research and development are warranted to fully realize their potential in treating various diseases.
  • These inhibitors offer a more precise approach to modulating BET-dependent transcriptional regulation.
Keywords:
BET inhibitorsBET phosphorylation sitesBET proteinsBRD4IDRextra-terminal domain

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.0K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.4K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
73